Cancer immunotherapy is coming of age; it has prompted a paradigm shift in oncology, in
which therapeutic agents are used to target immune cells rather than cancer cells. The first …

Although kinase inhibitors raise hope for people with cancer, patients and their clinicians
are commonly confronted with the cutaneous side-effects that are associated with the use of …

Increasing knowledge of the structure and function of the epidermal growth factor receptor (EGFR)
subfamily of tyrosine kinases and of their role in the initiation and progression of …

… Sandrine Faivre, Catherine Delbaldo, Karina Vera, Caroline Robert, Stéphanie Lozahic,
Nathalie Lassau, Carlo Bello, Samuel Deprimo, Nicoletta Brega, Giorgio Massimini, Jean-Pierre …

Purpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …

Purpose To establish the safety, tolerability, and pharmacokinetic parameters of CCI-779, a
selective inhibitor of the mammalian target of rapamycin, in patients with advanced cancer.

PURPOSE To review our experience using full-dose external reirradiation given with a curative
intent for patients with unresectable head and neck carcinoma (HNC). PATIENTS AND …

Among the group of head and neck cancers, nasopharyngeal carcinomas (NPC) represent
a distinct entity in terms of their epidemiology, clinical presentation, biological markers, …

PURPOSE A phase I study was undertaken to determine the maximum-tolerated dose (MTD),
principal toxicities, and pharmacokinetics of the novel topoisomerase I inhibitor irinotecan (…

The authors treated 14 patients with advanced squamous cell carcinoma (SCC) of the skin
or lip with one to four cycles of combination chemotherapy consisting of cisplatin by bolus …